아토피피부염 보습 치료: WHO 인증 황금레시피 공개

Why the WHO’s “Golden Recipe” Is a Game‑Changer for Atopic Dermatitis Care

In a historic move, the World Health Organization (WHO) has listed a specific moisturizer formula—15‑20% glycerol + 5% urea—in its 2025 Essential Medicines List. The decision validates what clinicians have known for decades: restoring the skin barrier is as crucial as controlling inflammation.

From “just a cream” to a prescription‑grade essential medicine

Until now, moisturizers were treated like cosmetics, with product claims ranging from “hydrating” to “clinical‑grade”. The WHO’s endorsement turns the tide, giving the formulation a medical status that will likely reshape prescribing habits, insurance reimbursement, and research funding worldwide.

Real‑world proof: The Dexeryl MD case study

French pharmaceutical group Pierre Fabre’s Dexeryl MD cream—the only product that matches the WHO’s recipe—has already shown impressive results:

• A multicenter trial with 335 children (2‑6 years) cut the 12‑week relapse rate from 67.6 % (no moisturizer) to 35.1 %.
• In a crossover study on 54 adults, adding the cream to steroid therapy accelerated severity reduction from 14.4 % to 24.5 % after 3 days.
• Long‑term follow‑up showed only 1 relapse out of 45 patients who continued the cream alone, versus 6 relapses in the non‑treated group.

These data illustrate how a scientifically‑backed moisturizer can dramatically lower flare‑ups and reduce reliance on steroids.

Future Trends Shaped by the WHO’s Decision

1. Standardised “Barrier‑Repair” Prescriptions

Dermatologists will likely begin writing prescriptions for the WHO formula instead of recommending over‑the‑counter (OTC) products. Expect electronic health record (EHR) templates that automatically suggest a glycerol‑urea cream for any new atopic dermatitis diagnosis.

2. Insurance Coverage Expands

Because the product is now an essential medicine, national health systems and private insurers may cover up to 100 % of the cost, as Pierre Fabre already reports for South Korea. This will lower financial barriers for patients, especially families with multiple children.

3. Personalized Barrier‑Care Platforms

Emerging digital tools—smart skin sensors, AI‑driven apps, and tele‑dermatology—will monitor transepidermal water loss (TEWL) in real time and recommend dosage adjustments for the glycerol‑urea cream. Companies are already piloting “moisture‑tracker” wearables that sync with patient portals.

4. New Formulations & Delivery Systems

Pharma R&D will explore nano‑emulsions, lipid‑based vesicles, and spray‑on technologies that retain the WHO‑approved concentrations while improving texture and patient adherence.

5. Global Regulatory Alignment

Countries may harmonise their drug‑approval pathways for moisturizers, creating a fast‑track “Barrier‑Repair” category similar to vaccines. This could speed up market entry for generics that meet the exact glycerol‑urea ratios.

Practical Tips for Clinicians and Caregivers

Implementing the WHO formula in daily practice

1. Assess skin barrier integrity with a simple TEWL test or visual scoring.
2. Prescribe the glycerol‑urea cream twice daily for at least 4 weeks, even during remission.
3. Combine with low‑potency steroids only for acute flares; taper steroids as the barrier improves.
4. Educate patients on “wet‑wrap” techniques to enhance absorption during severe episodes.

Frequently Asked Questions

Is the glycerol‑urea cream safe for infants?

Yes. The WHO classifies it as a “physiological substance” safe for all ages, including newborns.

Do I need a doctor’s prescription?

In most markets the cream is registered as a medical device, so a prescription is required for insurance coverage.

Can I use the cream together with other moisturizers?

Layering with a non‑emollient lotion may dilute the active concentrations; it’s best to use the WHO‑approved formula as the sole barrier‑repair product.

How long does it take to see improvement?

Clinical studies report visible reduction in dryness and erythema within 7‑10 days, with significant flare‑reduction after 2‑3 weeks.

Will insurance reimburse the cost?

Many national health plans already cover 60‑100 % of the expense when the product is prescribed.

Looking Ahead

As the glycerol‑urea formula becomes the global benchmark, we can anticipate a surge in evidence‑based skincare, tighter integration of barrier therapy into chronic disease management, and broader patient access through insurance. For anyone dealing with atopic dermatitis—whether a dermatologist, pediatrician, or parent—staying ahead of these trends will mean fewer flares, less steroid dependence, and healthier skin for life.